The UAE has taken a big step in healthcare by approving Itvisma (onasemnogene abeparvovec), a gene therapy to treat spinal muscular atrophy (SMA) in adults and children aged two years and older. This makes the UAE just the second country globally to approve this treatment, providing new hope to patients and their families. Itvisma works by replacing the faulty gene that causes SMA. This helps improve patients' muscle movement and reduces their need for long-term treatments. The Emirates Drug Establishment (EDE) gave the approval after reviewing clear clinical evidence showing lasting improvement in motor skills and a strong safety record. Dr. Fatima Al Kaabi, Director General of EDE, said, "The decision reflects the UAE’s commitment to providing patients with cutting edge genetic therapies, particularly for rare diseases, while highlighting the efficiency and scientific rigor of the country’s regulatory system." She added, "The UAE’s model balances speed, transparency, and safety, ensuring that innovative treatments reach patients in a timely and reliable manner." Novartis, the maker of Itvisma, sees this approval as a major milestone in patient care. Mohamed Ezz Eldin, Head of the GCC Cluster at Novartis, said, "Close collaboration with EDE and partners will enable fast and equitable access for patients who previously could not benefit from one-time gene therapy." He also stated, "The UAE’s support for advanced treatments can change the disease trajectory of SMA and aligns with Novartis’s broader focus on neurology, neurodegenerative disorders, and neuromuscular diseases." This approval also boosts the UAE’s standing as a regional center for pharmaceutical innovation. It shows the country's dedication to a modern, efficient healthcare system focused on knowledge and patient care. The UAE continues to improve the lives of patients across the region by making advanced therapies available quickly and safely.